Loews Corp (L)
$34.94 0.00 (0.00%)
19:00 EDT L Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 11.16B
PE Ratio 10.07
Volume (Avg. Vol.)
Day's Range 34.94 - 34.94
52-Week Range 27.33 - 56.88
Dividend & Yield 0.25 (0.72%)
L Stock Predictions, Articles, and Loews Corp News
- From InvestorPlace
- From the Web
The deal doubles LVMH’s jewelry market share to 18%. More importantly, it is by far the conglomerate’s biggest acquisition in its history. Including the Tiffany deal, it has made 20 deals worth $28 billion since the start of 2016.
It's hard to find stocks to buy trading for less than book since the S&P 500's 20% year to date gain. Here are 10 worth considering.
Battered and bruised, these seven stocks to buy on the dip will make patient investors some money in the long run.
Ted Seides might not have been able to beat Buffett, but these seven S&P 500 stocks will.
It pays to stay on top of the latest profit opportunities, and my updated Portfolio Grader ratings are a great place to start
The following stocks were the biggest movers and shakers in the Financial sector today.
During these times it pays to stay on top of the latest profit opportunities, and today's Portfolio Grader updated ratings is a great place to start
A Victoria's Secret model has ended her stint with the company after being told to lose weight. Erin Heatherton was informed by the lingerie retailer that....
During these times it pays to stay on top of the latest profit opportunities. Today's blog post should is a great place to start with our updated rankings
Financial stocks finished up 0.8% on Wall Street on Wednesday.
Financial stocks declined broadly on Wall Street on Monday morning, with the sector seeing an overall decline of 0.4%.
Financial stocks finished flat today on Wall Street.
From Seeking Alpha
Loews Hotels & Co, a wholly owned subsidiary of Loews (L +1.6%), announced that Alex Tisch will assume the role of President; will continue to lead the commercial, acquisitions & development, and the Loews Hotels at Universal Orlando Resort teams.Tisch joined Loews Hotels & Co in June 2017 from Loews, where he served as VP.In his last role at Credit Suisse, Tisch arranged leveraged buyout financings along with handling merger and acquisition advisories.
From Seeking Alpha
Scholar Rock (NASDAQ:SRRK) has dosed the first patient with SRK-181 in combination with anti-PD-(NYSE:L)1 therapy, in Part A2 of the DRAGON Phase 1 trial that consists of two parts, A and B, to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of SRK-181 in adult patients with locally advanced or metastatic solid tumors.Part A dose escalation portion of the trial is evaluating SRK-181 as both a monotherapy (Part A1) and in combination with approved anti-PD-(L)1 therapy (Part A2). Part A1 and Part A2 are being conducted in a parallel and will each evaluate doses up to 2400 mg.An update from Part A dose escalation is expected in the next quarter.Part B dose expansion portion of the trial is expected to initiate in Q1 of 2021 and will evaluate SRK-181 in combination with approved anti-PD-(L)1 therapy in multiple tumor-specific cohorts, and will enroll patients who are resistant to anti-PD-(L)1 therapy.SRK-181 is a selective inhibitor of latent TGFβ1 activation
Navellier RatingsPowered by Portfolio Grader